Evidence map›Paper›PMID 40267023›Full record

ArticleCancer2025

Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries.

Anne K Harris, Alexander T Nelson, Dave Watson, Paige H R Mallinger, Yoav H Messinger, A Lindsay Frazier, Allen Stering, Stacy L Snyder, Carolyn Fein Levy, Junne Kamihara and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Anne K HarrisInternational Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-3371-3096
Alexander T NelsonInternational Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.
Dave WatsonResearch Institute, Children's Minnesota, Minneapolis, Minnesota, USA.
Paige H R MallingerInternational Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.
Yoav H MessingerInternational Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.
A Lindsay FrazierPediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
Allen SteringWalter Reed National Military Medical Center, Bethesda, Maryland, USA.
Stacy L SnyderPediatric Hematology/Oncology, Beacon Health System, South Bend, Indiana, USA.
Carolyn Fein LevyPediatric Hematology/Oncology, Northwell Health, New Hyde Park, New York, USA.
Junne KamiharaPediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-2852-7387
Cynthia E HerzogDivision of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Joanne LagmayDivision of Hematology & Oncology, Department of Pediatrics in the College of Medicine, University of Florida, Gainesville, Florida, USA.
Steve ForestoPediatric Oncology, Queensland Children's Hospital, South Brisbane, Queensland, Australia.
Kenneth S ChenChildren's Medical Center Research Institute, UT Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0003-2304-4631
Kyle M DevinsJames Homer Wright Pathology Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-8097-2437
Robert H YoungJames Homer Wright Pathology Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
D Ashley HillLauren V. Ackerman Laboratory of Surgical Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Louis P DehnerLauren V. Ackerman Laboratory of Surgical Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Anil K TadavarthyHospital Pathology Associates, Minneapolis, Minnesota, USA.
Jennifer N StallHospital Pathology Associates, Minneapolis, Minnesota, USA.
Deborah F BillmireDivision of Pediatric Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Dominik T SchneiderClinic of Pediatrics, Municipal Hospital Dortmund, University Witten/Herdecke, Witten, Germany.ORCID https://orcid.org/0000-0001-8153-1601
Kris Ann P SchultzInternational Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-1788-5832

Funding

Detecting DICER1: A global partnership to cure pediatric lung cancerR37CA244940 · NCI · CHILDREN'S HOSPITALS AND CLINICS · PI Kris Ann Pinekenstein Schultz · 2020 to 2026
$2.4M
Children's Minnesota FoundationChildren's Minnesota Internal Research Grant ProgramHyundai Hope on Wheels Foundation#livelikemeganNCI NIH HHS R37 CA244940NCI NIH HHS R37CA244940Pine Tree Apple Classic Fund
6 · The paper itself

Abstract

backgroundOvarian juvenile granulosa cell tumors (juvGCT) are rare sex cord-stromal tumors that occur primarily in children and adolescents. This study summarizes the clinical presentation and outcomes of patients with juvGCT.

methodsPatients were enrolled in the International Ovarian and Testicular Stromal Tumor and/or International Pleuropulmonary Blastoma/DICER1 Registries. Available medical records were abstracted, and pathology was centrally reviewed. Surgical staging was classified using the 2014 International Federation of Gynecology and Obstetrics (FIGO) criteria.

resultsIn total, 70 patients with juvGCT enrolled and were diagnosed between 2001 and 2024; most patients (81%, 57 of 70) presented with FIGO stage I disease. Adjuvant chemotherapy was given in 30% (21 of 70); all regimens were platinum-based. Three-year event-free survival among patients with stage IA tumors was 80.2% (95% confidence interval [CI], 62.4%-100.0%), IC1 was 87.4 (95% CI, 72.4%-100.0%), IC2-IC3 was 63.6% (95% CI, 40.7%-99.5%), and II-IV was 48% (95% CI, 24.6%-93.8%). Of the patients with recurrent juvGCT with known mitotic index (MI), all had MI greater than 19 mitoses per 10 high power fields (HPF) at diagnosis.

conclusionOutcomes were worse for patients with FIGO stage ≥IC2 disease and for tumors with >19 mitoses per 10 HPF. Given the prognostic significance of MI, the authors strongly recommend the assessment of MI for all juvGCTs. More information about tumor biology is critical to identify which patients may benefit from adjuvant chemotherapy and to facilitate the development of novel therapies.

Indexed as

Granulosa Cell TumorOvarian NeoplasmsPulmonary BlastomaTesticular NeoplasmsAdolescentAdultChemotherapy, AdjuvantChildChild, PreschoolDisease-Free SurvivalFemaleHumansLung NeoplasmsMaleNeoplasm StagingPrognosisjuvenile granulosa cell tumormitotic indexovarian tumorpediatric cancerrare cancersex cord‐stromal tumor

Identifiers

PMID40267023
PMCPMC12305807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.